PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportspancreatic ductal carcinoma
MeSH D021441 - pancreatic ductal carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D010190:Pancreatic neoplasms
$
Success rate
D044584:Ductal carcinoma
0 Companies
0 Drugs
Success rate
D021441: 
Pancreatic ductal carcinoma
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaGemcitabine Gemcitabine  2011-01-25   
Novast LaboratoriesGemcitabine Gemcitabine  2019-02-14   
MylanGemcitabine Gemcitabine  2011-07-25   
Eli LillyGemcitabine Gemzar  1996-05-15   
Dr Reddys LaboratoriesGemcitabine Gemcitabine  2011-07-25   
Sun Pharmaceutical IndustriesGemcitabine Gemcitabine  2011-07-25   
Gemcitabine Infugem 2033-07-01 2018-07-16   
ApotexGemcitabine Gemcitabine  2017-05-23   
HospiraGemcitabine Gemcitabine  2011-07-25   
Accord HealthcareGemcitabine Gemcitabine  2011-07-25   
Hikma PharmaceuticalsGemcitabine Gemcitabine  2021-06-25   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
57%
42/74
Phase 2
18%
11/62
Phase 3
21%
4/19
Approved: 1Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Eli Lilly
Accord Healthcare
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use